Lara Sullivan, Pyxis Oncology CEO

Pyx­is tak­ing scalpel to pre­clin­i­cal pipeline, stops de­vel­op­ment on half — for now

A Cam­bridge, MA biotech is look­ing to push to the clin­ic, and it’s will­ing to throw oth­er can­di­dates to the way­side.

Pyx­is On­col­o­gy put out word Mon­day morn­ing in its Q2 earn­ings re­lease that the com­pa­ny is shift­ing its short-term em­pha­sis — fo­cus­ing on two pro­grams and ei­ther paus­ing or ceas­ing work on three more.

“We have elect­ed to sharp­en our near-term fo­cus on the clin­i­cal ex­e­cu­tion of our two most ad­vanced pro­grams, an­ti-EDB An­ti­body Drug Con­ju­gate (ADC), PYX-201, and an­ti-Siglec-15 mon­o­clon­al an­ti­body (mAb), PYX-106,” CEO Lara Sul­li­van said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.